Filtered By:
Source: Circulation: Cardiovascular Quality and Outcomes

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 429 results found since Jan 2013.

Abstract 314: Impact of Spontaneous Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial Session Title: Poster Session III
CONCLUSION: Spontaneous bleeding events are associated with a negative impact on health state utility, with greatest immediate impact for major bleeds. Health state utility remains low 1 year after an ICH, but gradually returns to baseline 1-year after other major bleeding events. Future cost-effectiveness analysis of strategies to prevent stroke in AF should consider both the economic and health status impact of bleeding events to inform health care decision making.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Magnuson, E. A., Wang, K., Li, H., Kwong, W. J., Antman, E. M., Ruff, C. T., Murphy, S. A., Giugliano, R. P., Cohen, D. J. Tags: Session Title: Poster Session III Source Type: research

Abstract 320: Healthcare Resource Utilization Among Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention and Using Prasugrel or Ticagrelor: A Retrospective Database Analysis Session Title: Poster Session III
Conclusions: All-cause rehospitalizations at 30-and 90-days post discharge in ACS-PCI pts were non-inferior with pras vs. ticag in all 3 cohorts. Pras was associated with significantly lower risk for 90-day all-cause rehospitalizations compared with ticag in the label and core cohorts, which are the majority of pts receiving pras. Although there appears to be inherent bias and unmeasured confounders related to use of pras vs. ticag, these data show reductions in HCRU with pras compared with ticag in the real-world setting at 30- and 90-days post-discharge.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Molife, C., Effron, M. B., DeKoven, M., Karkare, S., Frech-Tamas, F., Larmore, C., Zhu, Y., Lu, J., Lee, W. C., Mc Collam, P., Marrett, E., Vetrovec, G. W. Tags: Session Title: Poster Session III Source Type: research

Abstract 336: Real-World Experiences with Novel Anticoagulants for AF: Initial Insights from ORBIT-AF Phase II Session Title: Poster Session III
Conclusions: Patients with new-onset AF are frequently treated with novel anticoagulants and these patients have lower risk scores than those with known AF transitioned to a novel drug. These data will provide insights into clinical management and patient centered outcomes among those treated with novel anticoagulants in real world practice settings.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Steinberg, B. A., Milford-Beland, S., Ollis, D., Blanco, R., Ansell, J., Fonarow, G. C., Gersh, B., Go, A., Hylek, E., Kowey, P. R., Mahaffey, K. W., Thomas, L., Chang, P., Peterson, E. D., Piccini, J. P. Tags: Session Title: Poster Session III Source Type: research

Abstract 340: Thirty-day Repeat Hospitalizations for Patients Treated with Prasugrel Compared to Ticagrelor following Acute Coronary Syndrome: Findings from a Large Hospital Charge Master Database Session Title: Poster Session III
Conclusion: Rehosp for MI, revasc or bleeding was non-inferior for pras compared to ticag at 30 days post discharge. Pts treated with pras had lower 30 day rehosp rates, particularly related to readmission for MI, compared with ticag. Although limited by selection bias, these results support the clinical utility of pras, regardless of cohort, to limit 30 day rehosp for pts undergoing PCI for ACS.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Vetrovec, G. W., Larmore, C., Molife, C., DeKoven, M., Karkare, S., Zhu, Y. E., Frech-Tamas, F., Lu, J., Lee, W. C., Mc Collam, P., Marrett, E., Effron, M. B. Tags: Session Title: Poster Session III Source Type: research

Abstract 374: Quality Improvement Program to Optimize Pre-Operative Evaluation of Elective Cardiovascular Surgery Patients Reduces Complications and Improves Length of Stay Session Title: Poster Session III
Conclusions: A standardized pre-operative evaluation protocol in combination with prophylactic amiodarone in appropriate patients was associated with lower overall complications and a reduction in post-operative AF and LOS. Standardized protocols may enable health care providers to optimize pre-operative management of elective surgery patients and improve care quality and outcomes.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Porten, B. R., Strauss, C. E., Mueller, J. J., Garberich, R. F., Sun, B. C., Abdelhadi, R. H., Henry, T. D. Tags: Session Title: Poster Session III Source Type: research

Abstract 385: The Impact of Aspirin Primary Prevention Treatment Guidelines: Temporal Trends in Aspirin Use for Primary vs Secondary Prevention, 2005-2013 Session Title: Poster Session III
Conclusion: Secondary prevention ASA use in primary care settings remains high, but ASA use for primary prevention of cardiovascular events is low. Despite creation of national guidelines, aspirin use in the PP population is half the rate of ASA use for secondary prevention. Additional methods to safely and effectively disseminate this primary prevention aspirin use recommendation, targeting both the public and health care providers, are warranted.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Van't Hof, J. R., Oldenburg, N., Duval, S., Dronca, S., Olson, A., Peterson, K., Leupker, R. V., Miller, K., Hirsch, A. T. Tags: Session Title: Poster Session III Source Type: research

Abstract 157: An Early Assessment of Hospital Readmissions Among Nonvalvular Atrial Fibrillation Treated with the New Oral Anticoagulants, Apixaban, Dabigatran, and Rivaroxaban Session Title: Poster Session I
Conclusion: In this early assessment, treatment with rivaroxaban vs. apixaban was associated with greater risk of all-cause or bleeding-related 1-month readmissions and higher hospital costs due to readmissions.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Deitelzweig, S., Bruno, A., Trocio, J., Tate, N., Lin, J., Lingohr-Smith, M. Tags: Session Title: Poster Session I Source Type: research

Abstract 166: Developing the Veterans Affairs Cardiac Risk Score Session Title: Poster Session I
Conclusion: We demonstrated that an EHR in a specific population could risk-stratify patients as well those from as organized cohort studies and greatly improve calibration. Further, our finding that the ASCVD score greatly underpredicted in our population, while previous work have reported the ASCVD over-predictind in other cohorts, suggests that rather than arguing about which risk tool is best, our patients may be better served by us focusing on calibrating CV risk tools for our specific patient population using their EHR data.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Sussman, J. B., Wiitala, W., Hofer, T., Zawitowski, M., Vijan, S., Hayward, R. Tags: Session Title: Poster Session I Source Type: research

Abstract 174: Clinical Prediction Models for Cardiovascular Disease: The Tufts PACE CPM Database Session Title: Poster Session I
Conclusions: There is an abundance of CPMs available for many CVD conditions, with substantial redundancy in the literature. The comparative performance of these models, the consistency of effects and risk estimates across models and the actual and potential clinical impact of this body of literature is poorly understood.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Wessler, B. S., Lai YH, L., Kramer, W., Cangelosi, M., Raman, G., Lutz, J., Kent, D. M. Tags: Session Title: Poster Session I Source Type: research

Abstract 221: Outcomes Associated with Warfarin Time in Therapeutic Range Among Nonvalvular Atrial Fibrillation Patients Treated in an Integrated Healthcare Delivery System in the U.S. Session Title: Poster Session II
Conclusions: NVAF patients with low warfarin TTR, in comparison to those with high warfarin TTR, used more healthcare resources resulting in higher healthcare costs.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Deitelzweig, S., Evans, M., Hillson, E., Trocio, J., Bruno, A., Tan, W., Lingohr-Smith, M., Lin, J. Tags: Session Title: Poster Session II Source Type: research

Abstract 225: Frequency and Assessment of Poor Global Outcome in Patients with Left Ventricular Assist Devices Session Title: Poster Session II
Conclusion: In this large, single-center study assessing global outcome after LVAD implantation, we found that about a third of all patients had experienced a poor global outcome at 1 year. While LVAD therapy remains life-saving and the standard of care for many patients with advanced heart failure, these findings could help guide discussions with eligible patients and families. Future work should compare patients’ pre-LVAD expectations with likely outcomes and create risk models to estimate the probability of poorer outcomes for individual patients using pre-procedural factors.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Fendler, T. J., Nassif, M. E., Kennedy, K. F., Spertus, J. A., LaRue, S. J., Vader, J. M., Silvestry, S. C., Joseph, S. M., Arnold, S. V. Tags: Session Title: Poster Session II Source Type: research

Abstract 234: Comparison of Hospital Length of Stay and Costs between Non-valvular Atrial Fibrillation Patients Treated with Either Apixaban or Warfarin Session Title: Poster Session II
Conclusions: NVAF patients treated with apixaban had significantly shorter hospital LOS and lower index hospitalization costs compared to those treated with warfarin. Costs remained significantly lower for apixaban patients across all CHADS2 scores.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Xie, L., Vo, L., Keshishian, A., Price, K., Singh, P., Mardekian, J., Bruno, A., Baser, O., Kim, J., Tan, W., Trocio, J. Tags: Session Title: Poster Session II Source Type: research

Abstract 283: Association of Body Mass Index with Outcomes in Patients with Atrial Fibrillation: Results From the ORBIT-AF Registry Session Title: Poster Session II
Conclusion: Among patients with AF, higher BMI was associated with a greater use of anticoagulation, rhythm control strategies, and lower mortality risk.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Pandey, A., Gersh, B., McGuire, D., Shrader, P., Thomas, L., Kowey, P. R., Mahaffey, K. W., Hylek, E., Sun, S., Burton, P., Piccini, J., Peterson, E., Fonarow, G. Tags: Session Title: Poster Session II Source Type: research

Abstract 307: Gender Differences in Recurrent Cardiovascular Events Among High-risk Patients With Hyperlipidemia Session Title: Poster Session III
Conclusions: Among high-risk patients (i.e. history of CV events) enrolled in US health plans, women were more likely to have a subsequent CV event and multiple CV events sooner than men. Further research is needed to ascertain whether the gender differences might reflect differences in the intensity of treatment for hyperlipidemia between men and women.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Richhariya, A., Fox, K. M., Punekar, R. S., Gandra, S. R., Fisher, M. D., Cziraky, M. J., Toth, P. P. Tags: Session Title: Poster Session III Source Type: research

Abstract 328: Cardiovascular Disease Associated with Ability to Achieve Renal Transplant and Post-Transplant Adverse Events Session Title: Poster Session III
Conclusions: CVD is common in patients listed for renal transplant. CAD is independently associated with lower odds of receiving a transplant. CAD and rEF are independently associated with increased hazard of post-transplant death or graft failure. Future efforts should focus measures to optimize outcomes in patients with CVD awaiting transplant.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Ismail, S. J., Patel, M., Gindi, R., Salah, A., Tang, I., Benedetti, E., Ardati, A. Tags: Session Title: Poster Session III Source Type: research